Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus Gemcitabine in Advanced/Metastatic Pancreatic Cancer
NCT00789633Phase 3Completed
- Sponsor
- AB Science
- Start
- Nov 2008
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in Pancreatic ductal adenocarcinoma (PDAC) comparing Masitinib & gemcitabine with Placebo & gemcitabine (2 arms). Primary endpoint: Overall Survival up to 60 months. Started Nov 2008; status: completed.
02
Drugs
masitinib
03
Conditions
Pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00789633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00789633.